# Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)

> **NCT03446612** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** Daprodustat
- **DRUG:** Darbepoetin alfa
- **DRUG:** Acetylcholine
- **DRUG:** Sodium nitroprusside
- **DRUG:** L-N-monomethyl arginine acetate (L-NMMA)

## Key facts

- **NCT ID:** NCT03446612
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-10
- **Primary completion:** 2019-05-29
- **Final completion:** 2019-05-29
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study is terminated due to feasibility in recruitment.
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446612, "Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03446612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*